The conference highlighted strong commercial uptake and safety of the CAR T-cell therapy, with expanding indications in leukemia, pediatrics, and autoimmune diseases. Multiple pivotal trials and data readouts are expected through 2028, supporting further growth and market expansion.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.